BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 24330766)

  • 21. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
    Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
    EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
    Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
    J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
    Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z
    Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
    Yang F; Li QJ; Gong ZB; Zhou L; You N; Wang S; Li XL; Li JJ; An JZ; Wang DS; He Y; Dou KF
    Technol Cancer Res Treat; 2014 Feb; 13(1):77-86. PubMed ID: 23862748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
    Liu K; Liu S; Zhang W; Jia B; Tan L; Jin Z; Liu Y
    Oncol Rep; 2015 Aug; 34(2):1003-10. PubMed ID: 26045065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Lin YT; Chao CC
    Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
    Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
    Rigalli JP; Ciriaci N; Arias A; Ceballos MP; Villanueva SS; Luquita MG; Mottino AD; Ghanem CI; Catania VA; Ruiz ML
    PLoS One; 2015; 10(3):e0119502. PubMed ID: 25781341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.
    Potenza N; Mosca N; Zappavigna S; Castiello F; Panella M; Ferri C; Vanacore D; Giordano A; Stiuso P; Caraglia M; Russo A
    J Cell Physiol; 2017 Jul; 232(7):1907-1913. PubMed ID: 27982429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
    Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
    Peng HS; Liao MB; Zhang MY; Xie Y; Xu L; Zhang YJ; Zheng XF; Wang HY; Chen YF
    PLoS One; 2014; 9(6):e100814. PubMed ID: 24956259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
    Abeni E; Salvi A; Marchina E; Traversa M; Arici B; De Petro G
    Int J Oncol; 2017 Jul; 51(1):128-144. PubMed ID: 28560380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
    Lu AQ; Lv B; Qiu F; Wang XY; Cao XH
    Oncol Rep; 2017 Apr; 37(4):2071-2078. PubMed ID: 28350139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
    Xu YY; Chen L; Wang GL; Zhou JM; Zhang YX; Wei YZ; Zhu YY; Qin J
    BMC Cancer; 2013 Nov; 13():527. PubMed ID: 24195809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.